Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115059

Transforming growth factor-beta and suppression of humoral immune responses in HIV infection.

J Kekow, W Wachsman, J A McCutchan, W L Gross, M Zachariah, D A Carson, and M Lotz

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Kekow, J. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Wachsman, W. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by McCutchan, J. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Gross, W. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Zachariah, M. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Carson, D. in: PubMed | Google Scholar

Rheumaklinik Bad Bramstedt, Federal Republic of Germany.

Find articles by Lotz, M. in: PubMed | Google Scholar

Published March 1, 1991 - More info

Published in Volume 87, Issue 3 on March 1, 1991
J Clin Invest. 1991;87(3):1010–1016. https://doi.org/10.1172/JCI115059.
© 1991 The American Society for Clinical Investigation
Published March 1, 1991 - Version history
View PDF
Abstract

We reported previously that PBMC from HIV+ patients spontaneously release increased levels of TGF beta 1, contributing to defects in cellular immune responses. This study defines the implications of TGF beta overexpression for humoral immunity in HIV infection. We found that upon Staphylococcus aureus Cowan I (SAC) stimulation of cells from HIV+ donors, B-lymphocyte proliferative responses were decreased. This deficiency correlated closely (r = 0.7, P less than 0.001) with increased TGF beta secretion by PBMC from HIV-infected donors. Conditioned medium from HIV+ PBMC and purified TGF beta 1 had similar inhibitory effects on SAC- or EBV-induced B-cell proliferation, and B cells from HIV-infected donors were as sensitive to inhibition by TGF beta as cells from normal donors. Antibodies to TGF beta 1 neutralized the inhibitory effect of HIV+ culture supernatants on normal B cells and increased low proliferative responses by HIV+ cells. Using PWM as stimulus for B cell differentiation, it was shown that activated TGF beta from HIV+ PBMC is able to significantly reduce the induction of immunoglobulins and this effect was also abrogated by anti-TGF beta. These studies support the concept that in HIV infection, TGF beta is a potent suppressor, not only of the cellular, but of the humoral immune responses as well.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1010
page 1010
icon of scanned page 1011
page 1011
icon of scanned page 1012
page 1012
icon of scanned page 1013
page 1013
icon of scanned page 1014
page 1014
icon of scanned page 1015
page 1015
icon of scanned page 1016
page 1016
Version history
  • Version 1 (March 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts